Abstract
Researchers are avidly pursuing genetic explanations of why individuals respond differently to antidepressants. Investigators in the Genome-Based Therapeutic Drugs for Depression (GENDEP) study conducted a genome-wide exploration of 706 genetically unrelated European participants with unipolar major depression who received 12 weeks of escitalopram (which selectively inhibits the serotonin transporter without affecting norepinephrine reuptake) or nortriptyline (which has an 100-times-greater affinity for the …
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
